U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...

Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...

New research reveals how CBD and THC interact with brain receptors, unlocking potential for safer cannabis-based treatments.

Researchers have identified how CBD interacts with cannabinoid receptors to mitigate the negative effects of THC, the psychoactive component of cannabis.

University of Mississippi researchers have discovered how a compound found in cannabis might be used to mitigate the negative ...

Neuro effects are a risk for monlunabant and others in its drug class, which targets cannabinoid receptor type 1 (CB1). This receptor, found mainly in the central nervous system but also in some ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

The Food and Drug Administration (FDA) has granted Fast Track designation to PP-01 (nabilone/gabapentin) for the mitigation of cannabis withdrawal ...

Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...

Scientists reveal how CBD could help ease chronic pain, anxiety, and mood disorders. Researchers have uncovered a potential ...

Heavy lifetime cannabis use is associated with reduced brain activation in key cognitive regions, particularly during working ...